Qaam Pharmaceuticals, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Nov 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases (US 9,034,890) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
- 1 fee due Jan 21, 2027The maintenance fee for Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium (US 9,084,753) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Feb 13, 2027The maintenance fee for Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases (US 10,376,493) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Glycopyrronium Fatty Acid Salts and Methods of Making Same (US 10,519,109) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,969,402 | Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases In force · Medium confidence | In force | Medium confidence | |
| US 9,034,890 | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,980,941 | Quaternary ammonium anti-cholinergic muscarinic receptor antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 10,376,493 | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,419,850 | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,084,753 | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium In force · From the USPTO record | In force | From the USPTO record | |
| US 8,097,633 | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium In force · From the USPTO record | In force | From the USPTO record | |
| US 10,519,109 | Glycopyrronium Fatty Acid Salts and Methods of Making Same In force · High confidence | In force | High confidence | |
| US 12,109,202 | Fixed Dose Combination of Cholinesterase Inhibitor and a Quaternary Ammonium Antimuscarinic Agent to Treat Neurodegenerative Cognitive Disorders In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending